Abstract
Long-term survival in Diffuse Intrinsic Pontine Glioma (DIPG) is very rare. The purpose of this report is to detail the early (1988) use of IV Antineoplaston therapy (ANP {A-10 + AS2-1}) and its efficacy in DIPG while presenting the 27.7-year survival of a 36-year-old patient treated with ANP for progressive DIPG.
Highlights
Diffuse intrinsic pontine glioma (DIPG) originates in the glial cells of the pons, an integral part of the brain stem
BT-3 led to further Phase II clinical studies, which involved a more aggressive use of Antineoplaston Therapy (ANP), including continuous infusions of higher dose A10 and Antineoplaston AS2-1 (AS2-1) utilizing ambulatory infusion pumps
BT-3 led to further Phase II clinical studies, which involved the more aggressive use of ANP, especially continuous infusions of higher dose A10 and AS2-1, utilizing ambulatory infusion pumps, in accordance with BT-4 [7]
Summary
Diffuse intrinsic pontine glioma (DIPG) originates in the glial cells of the pons, an integral part of the brain stem. Gliomas can be low- or high-grade based on histological criteria and/or MRI findings. Individuals suffering from DIPG, a high-grade tumor, face a dismal prognosis with a median overall survival (OS) of approximately 11 months, and a 2 year survival rate of 10% [1,2]. Radiation therapy (RT) remains the standard of care for newly diagnosed DIPG, but only offers a survival benefit of approximately 3 months [3]. There is no standard of care for progressive DIPG after RT. Long-term survival in Diffuse Intrinsic Pontine Glioma (DIPG) is very rare. The purpose of this report is to detail the early (1988) use of IV Antineoplaston therapy (ANP {A-10 + AS2-1}) and its efficacy in DIPG while presenting the 27.7-year survival of a 36-year-old patient treated with ANP for progressive DIPG
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
